摘要： 目的 探讨平肝祛湿同治法对中青年社区高血压患者中医证候、不良事件及预后相关指标的影响。方法 选取中青年高血压患者132例，随机分为2组，剔除病例后，最终每组各64例纳入研究。对照组采用厄贝沙坦片治疗，观察组在对照组基础上加用平肝祛湿同治法治疗，均连续治疗2个月。比较2组血压、疗效、中医证候积分、安全性、不良事件、预后相关指标。结果 观察组中医和西医总有效率（96.88%、92.19%）均高于对照组（82.52%、78.13%），差异均有统计学意义（P =0.005，P =0.025）；治疗1、2个月后观察组血压、证候积分、醛固酮、血浆肾素活性、血浆血管紧张素Ⅱ、内皮素-1均低于对照组，一氧化氮高于对照组，差异均有统计学意义（均P < 0.05）；2组不良反应发生率比较，差异无统计学意义（P > 0.05）；观察组治疗期间不良事件发生率（1.56%）与对照组（10.94%）比较，差异无统计学意义（P > 0.05）。结论 平肝祛湿同治法治疗中青年高血压患者能进一步改善患者症状，提高血压控制效果，促进预后改善。

平肝祛湿同治法对中青年高血压患者中医证候、不良事件及预后相关指标的影响

柴松波¹, 杜亚康¹, 张淑娟², 兀江波³, 王晓飞¹

1. 三门峡市中医院心病科, 河南 三门峡 472000;
2. 河南中医药大学第二临床医学院心病科, 郑州 450002;
3. 三门峡市中医院药剂科, 河南 三门峡 472000

收稿日期:2023-03-02出版日期:2024-01-30发布日期:2024-01-09
通讯作者:柴松波E-mail:wdj123456780@126.com
作者简介:柴松波(1980-),男,副主任中医师,博士.
基金资助:国家自然科学基金（82204981）；河南省中医药拔尖人才培养项目专项课题（2022ZYBJ29）


关键词: 平肝祛湿同治法, 中青年, 高血压
Abstract: Objective To investigate the effects of the Pingan qushi prescription on traditional Chinese medicine syndrome, adverse events, and compliance in young and middle-aged hypertensive patients. Methods One hundred thirty-two young and middle-aged patients with hypertension were selected and randomly divided into two groups. After elimination, 64 cases were included in each group. For 2 months, the control group was treated with irbesartan tablets, and the observation group underwent the Pingan qushi prescription based on the control group. The blood pressure, curative effect, traditional Chinese medicine syndrome score, safety, adverse events, and prognosis-related indicators were compared between the two groups. Results The total effective rate of the observation group (96.88%, 92.19%) was higher than that of the control group (82.52%, 78.13%), and the difference was statistically significant (P=0.005, P=0.025). After 1 and 2 months of treatment, the blood pressure, syndrome scores, ALD, PRA, AngⅡ, and ET-1 in the observation group were lower than those in the control group, and the differences were statistically significant (all P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). There was no statistically significant difference (P > 0.05) in the incidence of adverse events during treatment between the observation group (1.56%) and control group (10.94%). Conclusion The treatment of young and middle-aged community patients with hypertension undergoing the Pingan qushi prescription can further improve patients' symptoms, increase blood pressure control, promote prognosis improvement.
Key words: Pingan qushi prescription, young and middle-aged, hypertension
PDF全文下载地址:

https://journal.cmu.edu.cn/CN/article/downloadArticleFile.do?attachType=PDF&id=3343